

One-Pot Approach to 2,3-Disubstituted-2,3-dihydro-4-quinolones from 2-Alkynylbenzamides

Noriko Okamoto,^{†,‡} Kei Takeda,[‡] Minoru Ishikura,[§] and Reiko Yanada^{*,†}


[†]Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan

[‡]Department of Synthetic Organic Chemistry, Graduate School of Medical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima 734-8553, Japan

[§]Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Hokkaido 061-0293, Japan

S Supporting Information

ABSTRACT: Concise and efficient syntheses of various *trans*-2,3-disubstituted-2,3-dihydro-4-quinolones have been achieved via tandem Hofmann-type rearrangement of 2-alkynylbenzamides, nucleophilic addition of alcohols to the isocyanate intermediates, intermolecular [2+2]-cycloaddition with carbon–carbon triple bonds and aldehydes, and intramolecular aminocyclization of nitrogen of carbamates to the α,β -unsaturated ketones.



Numerous synthetic methodologies for quinolone syntheses have been reported¹ because the ring system constitutes a basic structural unit of a large number of natural products,² synthetic intermediates,³ and bioactive molecules including antimitotic,⁴ antiviral,⁵ antibacterial,⁶ and anticancer⁷ agents and HIV-1 integrase inhibitors.⁸ Similarly, 2,3-dihydro-4-quinolones possess attractive pharmacological properties⁹ and also are used as important synthetic intermediates for the biologically active compounds.^{10,11} As part of our continuing interest in the syntheses of biologically active compounds using a tandem strategy, we have recently reported a procedure for the one-pot platinum(II)-catalyzed synthesis of indoles and isoquinolines via isocyanates, which were derived from a Hofmann-type rearrangement of amides **1** using a hypervalent iodine reagent.¹² A significant feature of this strategy is that relatively stable alkynylamides could be used as a starting material to efficiently furnish the indoles and isoquinolines in combination with the Hofmann-type rearrangement. As an extension of this approach, we now report our successful stereoselective synthesis of *trans*-2,3-dihydro-4-quinolones **4** featuring a tandem strategy that involves (1) Hofmann-type rearrangement of 2-alkynylbenzamides **1** followed by a nucleophilic addition of an alcohol to an isocyanate intermediate (**1** \rightarrow **2**), (2) acid-catalyzed intermolecular [2+2]-cycloaddition with carbon–carbon triple bonds of carbamates **2** and aldehydes (**2** \rightarrow **3**), and (3) acid-catalyzed intramolecular aminocyclization to the α,β -unsaturated ketones (**3** \rightarrow **4**) (Scheme 1).

A key to the success of this approach is whether an acid catalyst, required for the [2+2]-cycloaddition^{13,14} and the aminocyclization, can tolerate the presence of coproducts generated in the Hofmann-type rearrangement by the hypervalent iodine reagent. To explore this possibility, we examined the reaction using **1a**, readily available from Sonogashira coupling of 2-iodobenzamide and 1-hexyne, as a substrate (Table 1). After the treatment of **1a** with EtOH (4 equiv) in the presence of

hypervalent iodine (1 equiv) at 60 °C for 2 h, which is a procedure required to ensure the completion of the Hofmann-type rearrangement, benzaldehyde (1.5 equiv) and a Brønsted or Lewis acid catalyst were added. Without the addition of an external acid (Table 1, entry 1) and with Cu(OTf)₂ (Table 1, entry 2), the reaction stopped at the carbamate stage to give only **2a**. Most of the other acids afforded the desired quinolone derivative **4a** with high *trans*-selectivity together with **2a** and ketone **5a**,¹⁵ presumably produced from the acetic acid-catalyzed hydrolysis of alkyne **2a**, with various yields and in variable ratios. The best result was obtained with PhI(OCOCH₃)₂ and BF₃·Et₂O (1 equiv), which afforded **4a** in 73% yield with high *trans*-selectivity (Table 1, entry 7).

Having in hand the optimized conditions for the formation of **4a**, we further explored the scope of this reaction, particularly in regard to the substituents R¹ and R⁴, alcohol R²OH, and aldehyde R³CHO (Table 2). In most cases, moderate yields and high *trans*-selectivities of 2,3-disubstituted-2,3-dihydro-4-quinolones **4**¹⁶ were observed. In the presence of either electron-donating or moderately electron-withdrawing substituents R⁴ on the aromatic ring of 2-alkynylbenzamides **1**, the yields of desired products **4** ranged from 72–81% (Table 2, entries 1–3). However, the presence of the strongly electron-withdrawing nitro group on the aromatic ring slowed the [2+2]-cycloaddition reaction, giving carbamate **2e** exclusively (Table 2, entry 4). The use of benzyl alcohol as the nucleophile afforded only *N*-Cbz-protected 4-quinolone **4f** (Table 2, entry 5). When aliphatic aldehydes were used, 4-quinolones were also obtained with high *trans*-selectivities (Table 2, entries 10 and 11). 2-Alkynylbenzamides **1**, bearing an aromatic substituent on the terminus of the alkyne, also gave the corresponding 4-quinolone **4** in good yields (Table 2, entries 14 and 15). When *p*-cyanobenzaldehyde or *p*-

Received: August 5, 2011

Published: September 22, 2011

nitrobenzaldehyde were used as the aldehyde at 60 °C, intermolecular [2+2]-cycloaddition proceeded stereoselectively to give only the corresponding trisubstituted enones **3q** or **3r** with high (*E*)-selectivity¹³ accompanied by ketone **5a** (Table 2, entries 16 and 18). The configuration of the enone double bond of **3** was assigned on the basis of NOESY experiments. Fortunately, the same reactions at 90 °C gave the desired 4-quinolones **4q** and **4r** in high yields with *trans*-selectivities (Table 2, entries 17 and 19). To determine whether the *trans*-selectivity of the formation of **4** depends on the *E:Z*-configuration of enone **3**, we undertook the following experiment (Scheme 2). The stereoisomeric mixture of the enone **3q** (*E:Z* = 3:1) was derived from the enone **3q** (*E:Z* = 25:1, Table 2, entry 16) after being stored at room temperature for five months. Following the addition of $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (1 equiv) in DCE and stirring of the mixture at 90 °C for 24 h, the reaction afforded only *trans*-**4q** in 80% yield. Thus, the predominant *trans*-**4q** formation is not dependent on the *E:Z*-configuration of **3q**, and is presumably produced from normal 1,4-addition of carbamate nitrogen to α,β -unsaturated carbonyl compound **3**. Terminal alkyne **1f** was also suitable for this

Scheme 1. One-Pot Synthesis of 2,3-Disubstituted-2,3-dihydro-4-quinolones 4 from Amides 1





Table 1. Optimization of the Reaction Conditions^a



entry	hypervalent iodine	acid (1 equiv)	time (h)	4a (%) ^b (<i>trans</i> : <i>cis</i>) ^c	5a (%)	2a (%)
1	$\text{PhI}(\text{OCOCF}_3)_2$		20	trace	5	48
2	$\text{PhI}(\text{OCOCF}_3)_2$	$\text{Cu}(\text{OTf})_2$	20	0	0	64
3	$\text{PhI}(\text{OCOCF}_3)_2$	$\text{BF}_3 \cdot \text{Et}_2\text{O}$	20	60 (20:1)	0	0
4	$\text{PhI}(\text{OCOCF}_3)_2$	AgSbF_6	20	43 (18:1)	4	0
5	$\text{PhI}(\text{OCOCH}_3)_2$	SbF_5	24	trace	4	4
6	$\text{PhI}(\text{OCOCH}_3)_2$	AgOTf	24	5 (20:1)	5	10
7	$\text{PhI}(\text{OCOCH}_3)_2$	$\text{BF}_3 \cdot \text{Et}_2\text{O}$	18	73 (40:1)	0	0
8	$\text{PhI}(\text{OCOCH}_3)_2$	$\text{BF}_3 \cdot \text{Et}_2\text{O}$ (0.5 equiv)	18	48 (28:1)	9	12
9	$\text{PhI}(\text{OCOCH}_3)_2$	$\text{BF}_3 \cdot \text{Et}_2\text{O}$ (0.1 equiv)	24	15 (27:1)	8	35
10	$\text{PhI}(\text{OCOCH}_3)_2$	TfOH	24	8 (27:1)	4	8
11	$\text{PhI}(\text{OCOCH}_3)_2$	$\text{In}(\text{OTf})_3$	24	18 (24:1)	27	0
12	$\text{PhI}(\text{OTs})(\text{OH})$	$\text{BF}_3 \cdot \text{Et}_2\text{O}$	20	32 (18:1)	4	0

^a Amide (0.2 mmol), hypervalent iodine (0.2 mmol), EtOH (0.8 mmol), benzaldehyde (0.3 mmol), and acid (0.2 mmol) in $\text{ClCH}_2\text{CH}_2\text{Cl}$ (1 mL) were used except in entries 8 and 9. ^b Isolated yields. ^c Ratios were determined by ¹H NMR analysis.

reaction to afford **4s** (Table 2, entry 20). This reaction can be easily conducted on a scale of 7 mmol of **1f** (1.015 g) in a slightly higher yield (Table 2, entry 21). The reaction with benzophenone instead of aldehydes failed to give any of the desired cyclic compound **4t** at all (Table 2, entry 22).

In conclusion, we have demonstrated the synthesis of various *trans*-2,3-disubstituted-2,3-dihydro-4-quinolones from 2-alkynylbenzamide derivatives by a one-pot tandem process that involves a Hofmann-type rearrangement of 2-alkynylbenzamides, a nucleophilic addition of alcohols to the resulting isocyanate intermediates, an intermolecular [2+2]-cycloaddition with an alkyne triple bond and aldehydes, and an intramolecular aminocyclization to the α,β -unsaturated ketones.

EXPERIMENTAL SECTION


General Experimental Methods. ¹H NMR and ¹³C NMR spectra were recorded on a 600 MHz spectrometer. Chemical shifts are reported in δ (ppm) from tetramethylsilane as an internal standard. Data are reported as follows: chemical shifts, relative integration value, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), and coupling constants (Hz). Infrared spectra were obtained using an FT spectrometer. Analytical thin layer chromatography was performed on Merck silica gel 60 F254 TLC plates. Compounds **1a**,¹⁷ **1e**,¹⁷ **2a**,^{13d} **4a**,^{13d} **4l**,^{13d} **4r**,^{13d} and **5a**^{13d} are all known compounds. Experimental procedures and data for compounds **1b**, **1c**, **1d**, and **1f** have been reported in our previous paper.^{12a}

Ethyl 2-(Hex-1-ynyl)5-nitrophenylcarbamate (2e). White solid (56 mg, 97%): mp 84–85 °C; ¹H NMR (CDCl_3) δ 9.05 (1H, s), 7.81 (1H, dd, *J* = 8.4, 2.4 Hz), 7.50 (1H, s), 7.45 (1H, d, *J* = 8.4 Hz), 4.29 (2H, q, *J* = 7.3 Hz), 2.56 (2H, t, *J* = 7.2 Hz), 1.69–1.64 (2H, m), 1.55–1.49 (2H, m), 1.36 (3H, t, *J* = 7.3 Hz), 0.99 (3H, t, *J* = 7.6 Hz); ¹³C NMR (CDCl_3) δ 152.8, 147.5, 139.8, 131.9, 118.1, 116.9, 112.2, 103.0, 74.7, 61.9, 30.3, 22.0, 19.4, 14.4, 13.5; IR (CHCl_3 , cm^{-1}) 3398, 3035,

Table 2. One-Pot Synthesis of 4-Quinolone 4 from Benzamide 1

entry	alkyne	R ¹	R ²	R ³	R ⁴	temp (°C)	time (h)	4	(trans:cis) (%)	5 (%)	2 or 3 (E:Z) (%)
1	1a	Bu	Et	<i>p</i> -MeC ₆ H ₄	H	60	20	4b	81 (22:1)	0	0
2	1b	Bu	Et	<i>p</i> -MeC ₆ H ₄	OMe	60	16	4c	72 (7:1)	0	0
3	1c	Bu	Et	<i>p</i> -MeC ₆ H ₄	F	60	16	4d	80 (38:1)	5d 7	0
4	1d	Bu	Et	<i>p</i> -MeC ₆ H ₄	NO ₂	60	24	4e	0	0	2e 97
5	1a	Bu	Bn	<i>p</i> -MeC ₆ H ₄	H	60	20	4f	73 (8:1)	0	0
6	1a	Bu	Et	<i>o</i> -MeC ₆ H ₄	H	60	20	4g	82 (20:1)	0	0
7	1a	Bu	Et	<i>m</i> -MeC ₆ H ₄	H	60	20	4h	76 (33:1)	0	0
8	1a	Bu	Et	<i>p</i> -MeOC ₆ H ₄	H	60	24	4i	68 (98:1)	0	0
9	1a	Bu	Et	<i>p</i> -FC ₆ H ₄	H	60	20	4j	76 (25:1)	0	0
10	1a	Bu	Et	hexyl	H	60	20	4k	61 (20:1)	23	0
11	1a	Bu	Et	cyclohexyl	H	60	20	4l	87 (99:1)	0	0
12	1a	Bu	Me	Ph	H	60	20	4m	72 (28:1)	0	0
13	1b	Bu	Et	Ph	OMe	60	20	4n	52 (11:1)	0	0
14	1e	Ph	Me	<i>p</i> -MeC ₆ H ₄	H	60	16	4o	73 (trans)	0	0
15	1e	Ph	Et	<i>p</i> -MeC ₆ H ₄	H	60	16	4p	66 (trans)	0	0
16	1a	Bu	Et	<i>p</i> -CNC ₆ H ₄	H	60	32	4q	0	5a 19	3q 55 (25:1)
17	1a	Bu	Et	<i>p</i> -CNC ₆ H ₄	H	90	24	4q	82 (trans)	0	0
18	1a	Bu	Et	<i>p</i> -NO ₂ C ₆ H ₄	H	60	24	4r	0	5a 24	3r 59 (25:1)
19	1a	Bu	Et	<i>p</i> -NO ₂ C ₆ H ₄	H	90	24	4r	80 (trans)	0	0
20	1f	H	Et	<i>p</i> -MeC ₆ H ₄	H	60	20	4s	85	0	0
21 ^a	1f	H	Et	<i>p</i> -MeC ₆ H ₄	H	60	20	4s	88	0	0
22	1a	Bu	Et	(PhCOPh)	H	90	22	4t	0	5a trace	0

^aThe reaction was conducted with a 7 mmol (1.015 g) scale of 1f.

Scheme 2. Conversion of Enone 3q to *trans*-4q

1738, 1533, 1347, 1237, 1197, 819. MS (EI): $m/z = 290$ (M^+). HRMS (EI): m/z calcd for C₁₃H₁₈N₂O₄: 290.1267; found: 290.1274.

(*E*)-Ethyl 2-(2-(4-Cyanobenzylidene)hexanoyl)phenylcarbamate (3q). Pale yellow oil (41 mg, 55%): ¹H NMR (CDCl₃) δ 10.10 (1H, s), 8.41 (1H, d, $J = 8.9$ Hz), 7.70–7.69 (3H, m), 7.56 (1H, t, $J = 7.9$ Hz), 7.44 (2H, d, $J = 7.6$ Hz), 7.06 (1H, t, $J = 7.9$ Hz), 6.81 (1H, s), 4.24 (2H, q, $J = 6.9$ Hz), 2.68 (2H, t, $J = 7.9$ Hz), 1.54–1.49 (2H, m), 1.42–1.31 (5H, m), 0.91 (3H, t, $J = 7.2$ Hz); ¹³C NMR (CDCl₃) δ 201.2, 153.8, 145.6, 141.1, 140.1, 136.0, 134.3, 132.7, 132.3, 129.5, 123.0, 121.2, 120.0, 118.5, 111.8, 61.3, 30.6, 28.1, 22.9, 14.5, 13.8; IR (CHCl₃, cm⁻¹) 3230, 3034, 3009, 1728, 1630, 1582, 1524, 1449, 1238, 683. MS (EI): $m/z = 376$ (M^+). HRMS (EI): m/z calcd for C₂₃H₂₄N₂O₃: 376.1787; found: 376.1780.

(*E*)-Ethyl 2-(2-(4-Nitrobenzylidene)hexanoyl)phenylcarbamate (3r). Pale yellow oil (47 mg, 59%): ¹H NMR (CDCl₃) δ 10.13 (1H, s), 8.42 (1H, d, $J = 8.2$ Hz), 8.27 (2H, d, $J = 8.6$ Hz), 7.71 (1H, d, $J = 7.6$ Hz), 7.57 (1H, t, $J = 7.9$ Hz), 7.50 (2H, d, $J = 8.6$ Hz), 7.07 (1H, t, $J = 7.6$ Hz), 6.85 (1H, s), 4.24 (2H, q, $J = 6.9$ Hz), 2.70 (2H, t, $J = 7.9$ Hz), 1.54–1.51 (2H, m), 1.41–1.37 (2H, m), 1.33 (3H, t, $J = 6.9$ Hz), 0.91 (3H, t, $J = 7.2$ Hz); ¹³C NMR (CDCl₃) δ 201.1, 153.8, 147.2, 146.1, 142.0, 141.1, 135.3, 134.4, 132.7, 129.7, 123.8, 122.8, 121.2, 120.1, 61.3,

30.6, 28.2, 22.9, 14.5, 13.8; IR (CHCl₃, cm⁻¹) 3277, 3036, 3009, 1730, 1632, 1599, 1582, 1528, 1516, 1449, 1346, 1250, 1196, 1163, 1059. MS (EI): $m/z = 396$ (M^+). HRMS (EI): m/z calcd for C₂₂H₂₄N₂O₅: 396.1685; found: 396.1689.

General Procedure for One-Pot Synthesis of 2,3-Disubstituted-2,3-dihydro-4-quinolones 4 from 2-Alkynylbenzamides 1.

To a solution of 2-alkynylbenzamide 1 (0.20 mmol) and PhI(OAc)₂ (0.22 mmol) in 1,2-dichloroethane (1.0 mL) was added alcohol (0.80 mmol), and the mixture was stirred at 60 °C for 2 h. Then, aldehyde (0.30 mmol) and BF₃·Et₂O (0.20 mmol) was added, and the mixture was stirred at 60 or 90 °C for 16–32 h. After the completion of the reaction was confirmed by TLC, the reaction mixture was directly chromatographed on silica gel using hexane: ethyl acetate (10:1 to 5:1) as an eluent to afford the 2,3-disubstituted-2,3-dihydro-4-quinolone 4.

Ethyl 3-Butyl-4-oxo-2-*p*-tolyl-3,4-dihydroquinoline-1(2*H*)-carboxylate (4b). Pale yellow oil (59 mg, 81%): ¹H NMR (CDCl₃) δ 7.90–7.89 (2H, m), 7.47 (1H, t, $J = 7.9$ Hz), 7.08–7.04 (3H, m), 7.00 (2H, d, $J = 7.6$ Hz), 5.98 (1H, s), 4.46–4.32 (2H, m), 3.12 (1H, t, $J = 7.6$ Hz), 2.22 (3H, s), 1.81–1.71 (2H, m), 1.62–1.54 (1H, m), 1.50–1.43 (1H, m), 1.41–1.34 (5H, m), 0.92 (3H, t, $J = 6.9$ Hz); ¹³C NMR (CDCl₃) δ 195.9, 155.1, 141.1, 137.0, 135.3, 134.4, 129.2, 129.1, 127.3, 126.5, 123.8, 123.5, 62.7, 59.6, 51.1, 29.7, 29.2, 22.5, 20.8, 14.5, 13.8; IR (CHCl₃, cm⁻¹) 3036, 3007, 2961, 2932, 1706, 1682, 1601, 1479, 1460, 1396, 1381, 1321, 1298, 1269, 1242, 1196, 1049. MS (EI): $m/z = 365$ (M^+). HRMS (EI): m/z calcd for C₂₃H₂₇NO₃: 365.1991; found: 365.1991.

Ethyl 3-Butyl-7-methoxy-4-oxo-2-*p*-tolyl-3,4-dihydroquinoline-1(2*H*)-carboxylate (4c). Pale yellow oil (57 mg, 72%): ^1H NMR (CDCl_3) δ 7.78 (1H, d, $J = 8.9$ Hz), 7.39 (1H, s), 7.00 (2H, d, $J = 8.2$ Hz), 6.94 (2H, d, $J = 8.2$ Hz), 6.55 (1H, dd, $J = 8.6, 2.4$ Hz), 5.89 (1H, s), 4.38–4.23 (2H, m), 3.76 (3H, s), 2.98–2.95 (1H, m), 2.16 (3H, s), 1.68–1.27 (9H, m), 0.84 (3H, t, $J = 7.2$ Hz); ^{13}C NMR (CDCl_3) δ 194.8, 164.6, 155.0, 143.0, 137.1, 135.7, 129.4, 129.3, 126.5, 117.4, 111.1, 107.8, 62.8, 59.9, 55.5, 50.9, 30.0, 29.3, 22.6, 20.9, 14.5, 13.9; IR (CHCl_3 , cm^{-1}) 3036, 3009, 1706, 1696, 1603, 1447, 1310, 1272. MS (EI): $m/z = 395$ (M^+). HRMS (EI): m/z calcd for $\text{C}_{24}\text{H}_{29}\text{NO}_4$: 395.2097; found: 395.2091.

Ethyl 3-Butyl-7-fluoro-4-oxo-2-*p*-tolyl-3,4-dihydroquinoline-1(2*H*)-carboxylate (4d). Pale yellow oil (61 mg, 80%): ^1H NMR (CDCl_3) δ 7.91 (1H, t, $J = 7.6$ Hz), 7.72 (1H, d, $J = 10.3$ Hz), 7.04 (4H, q, $J = 7.8$ Hz), 6.77 (1H, td, $J = 8.2, 1.8$ Hz), 5.97 (1H, s), 4.45–4.34 (2H, m), 3.09 (1H, t, $J = 7.2$ Hz), 2.24 (3H, s), 1.76–1.69 (2H, m), 1.59–1.54 (1H, m), 1.47–1.34 (6H, m), 0.92 (3H, t, $J = 7.2$ Hz); ^{13}C NMR (CDCl_3) δ 194.5, 167.2, 165.6, 154.7, 143.2, 143.1, 137.3, 135.1, 130.1, 130.0, 129.4, 126.4, 120.0, 111.7, 111.6, 110.6, 110.4, 63.1, 59.9, 50.8, 29.7, 29.2, 22.5, 20.9, 14.4, 13.9; IR (CHCl_3 , cm^{-1}) 3037, 3008, 2962, 2933, 1711, 1684, 1610, 1585, 1487, 1443, 1397, 1381, 1305, 1266. MS (EI): $m/z = 383$ (M^+). HRMS (EI): m/z calcd for $\text{C}_{23}\text{H}_{26}\text{NO}_3\text{F}$: 383.1897; found: 383.1888.

Benzyl 3-Butyl-4-oxo-2-*p*-tolyl-3,4-dihydroquinoline-1(2*H*)-carboxylate (4f). Pale yellow oil (62 mg, 73%): ^1H NMR (CDCl_3) δ 7.88 (2H, d, $J = 6.9$ Hz), 7.46 (1H, t, $J = 7.6$ Hz), 7.40–7.34 (5H, m), 7.08–7.05 (3H, m), 6.99 (2H, d, $J = 7.6$ Hz), 5.97 (1H, s), 5.43 (1H, d, $J = 12.4$ Hz), 5.29 (1H, d, $J = 12.4$ Hz), 3.08 (1H, t, $J = 7.6$ Hz), 2.22 (3H, s), 1.70–1.66 (2H, m), 1.48–1.45 (1H, m), 1.40–1.35 (1H, m), 1.30–1.24 (2H, m), 0.85 (3H, t, $J = 7.2$ Hz); ^{13}C NMR (CDCl_3) δ 195.8, 155.0, 141.0, 137.2, 135.7, 135.3, 134.5, 129.3, 128.7, 128.5, 128.3, 127.4, 126.6, 124.0, 123.8, 123.6, 68.4, 60.0, 51.1, 29.8, 29.2, 22.5, 20.9, 13.9; IR (CHCl_3 , cm^{-1}) 3036, 3009, 2960, 1706, 1684, 1602, 1480, 1461, 1389, 1339, 1321, 1297, 1268, 1021. MS (EI): $m/z = 427$ (M^+). HRMS (EI): m/z calcd for $\text{C}_{28}\text{H}_{29}\text{NO}_3$: 427.2147; found: 427.2142.

Ethyl 3-Butyl-4-oxo-2-*o*-tolyl-3,4-dihydroquinoline-1(2*H*)-carboxylate (4g). White solid (60 mg, 82%): mp 69–70 °C; ^1H NMR (CDCl_3) δ 7.98–7.95 (2H, m), 7.55–7.52 (1H, m), 7.16–7.06 (3H, m), 6.90 (1H, t, $J = 7.6$ Hz), 6.82 (1H, d, $J = 8.2$ Hz), 6.07 (1H, s), 4.38–4.24 (2H, m), 2.85 (1H, t, $J = 7.2$ Hz), 2.41 (3H, s), 1.80–1.72 (2H, m), 1.63–1.58 (1H, m), 1.47–1.30 (6H, m), 0.91 (3H, t, $J = 7.6$ Hz); ^{13}C NMR (CDCl_3) δ 196.1, 154.8, 142.3, 137.3, 135.5, 134.7, 131.2, 127.6, 127.4, 126.1, 125.7, 123.8, 123.6, 62.8, 58.4, 51.6, 30.9, 29.2, 22.6, 19.6, 14.4, 13.9; IR (CHCl_3 , cm^{-1}) 3038, 3007, 1702, 1698, 1693, 1681, 1674, 1601, 1480, 1460, 1373, 1320, 1295, 1270. MS (EI): $m/z = 365$ (M^+). HRMS (EI): m/z calcd for $\text{C}_{23}\text{H}_{27}\text{NO}_3$: 365.1991; found: 365.1997.

Ethyl 3-Butyl-4-oxo-2-*m*-tolyl-3,4-dihydroquinoline-1(2*H*)-carboxylate (4h). Pale yellow oil (55 mg, 76%): ^1H NMR (CDCl_3) δ 7.89 (2H, dd, $J = 7.9, 1.7$ Hz), 7.50–7.47 (1H, m), 7.09–7.06 (2H, m), 7.00 (1H, s), 6.97–6.95 (2H, m), 5.98 (1H, s), 4.45–4.42 (1H, m), 4.36–4.33 (1H, m), 3.15–3.12 (1H, m), 2.23 (3H, s), 1.79–1.73 (2H, m), 1.60–1.57 (1H, m), 1.49–1.45 (1H, m), 1.41–1.36 (5H, m), 0.92 (3H, t, $J = 7.6$ Hz); ^{13}C NMR (CDCl_3) δ 195.9, 155.1, 141.3, 138.4, 138.2, 134.5, 128.5, 128.2, 127.5, 127.4, 123.8, 123.7, 123.6, 62.8, 59.8, 51.2, 29.8, 29.3, 22.5, 21.5, 14.5, 13.9; IR (CHCl_3 , cm^{-1}) 3038, 3008, 1700, 1686, 1681, 1602, 1480, 1461, 1380, 1322, 1297, 1269. MS (EI): $m/z = 365$ (M^+). HRMS (EI): m/z calcd for $\text{C}_{23}\text{H}_{27}\text{NO}_3$: 365.1991; found: 365.1989.

Ethyl 3-Butyl-2-(4-methoxyphenyl)-4-oxo-3,4-dihydroquinoline-1(2*H*)-carboxylate (4i). Pale yellow oil (52 mg, 68%): ^1H NMR (CDCl_3) δ 7.90 (1H, dd, $J = 7.6, 1.4$ Hz), 7.85 (1H, d, $J = 7.6$ Hz), 7.47 (1H, td, $J = 7.9, 1.8$ Hz), 7.12–7.06 (3H, m), 6.73 (2H, d, $J = 8.2$ Hz), 5.96 (1H, s), 4.45–4.34 (2H, m), 3.70 (3H, s), 3.11–3.08 (1H, m), 1.77–1.72 (2H, m), 1.61–1.55 (1H, m), 1.49–1.44 (1H, m), 1.39–1.35 (5H, m), 0.92 (3H, t, $J = 7.6$ Hz); ^{13}C NMR (CDCl_3) δ 196.1, 158.7, 155.1, 141.1, 134.5, 130.4, 127.9, 127.4, 123.8, 123.5, 113.9,

62.8, 59.4, 55.2, 51.1, 29.7, 29.3, 22.5, 14.5, 13.9; IR (CHCl_3 , cm^{-1}) 2961, 2934, 1682, 1601, 1514, 1479, 1462, 1396, 1381, 1321, 1298, 1271, 1252, 1034, 714. MS (EI): $m/z = 381$ (M^+). HRMS (EI): m/z calcd for $\text{C}_{23}\text{H}_{27}\text{NO}_4$: 381.1940; found: 381.1935.

Ethyl 3-Butyl-2-(4-fluorophenyl)-4-oxo-3,4-dihydroquinoline-1(2*H*)-carboxylate (4j). Pale yellow oil (56 mg, 76%): ^1H NMR (CDCl_3) δ 7.90 (1H, d, $J = 7.6$ Hz), 7.85 (1H, d, $J = 7.6$ Hz), 7.49 (1H, t, $J = 7.9$ Hz), 7.18–7.15 (2H, m), 7.09 (1H, t, $J = 7.6$ Hz), 6.89 (2H, t, $J = 8.6$ Hz), 5.98 (1H, s), 4.47–4.33 (2H, m), 3.11–3.08 (1H, m), 1.81–1.71 (2H, m), 1.62–1.53 (1H, m), 1.50–1.43 (1H, m), 1.41–1.34 (5H, m), 0.92 (3H, t, $J = 7.6$ Hz); ^{13}C NMR (CDCl_3) δ 195.7, 162.8, 161.1, 155.1, 140.9, 134.6, 134.3, 134.3, 128.4, 128.4, 127.5, 124.0, 123.8, 123.4, 115.6, 115.5, 63.0, 59.4, 51.2, 29.8, 29.2, 22.5, 14.5, 13.9; IR (CHCl_3 , cm^{-1}) 3036, 3009, 1684, 1602, 1512, 1480, 1461, 1380, 1323, 1297, 1269, 1163. MS (EI): $m/z = 369$ (M^+). HRMS (EI): m/z calcd for $\text{C}_{22}\text{H}_{24}\text{NO}_3\text{F}$: 369.1740; found: 369.1732.

Ethyl 3-Butyl-2-hexyl-4-oxo-3,4-dihydroquinoline-1(2*H*)-carboxylate (4k). Pale yellow oil (44 mg, 61%): ^1H NMR (CDCl_3) δ 7.98 (1H, dd, $J = 7.9, 1.7$ Hz), 7.81 (1H, br), 7.54–7.51 (1H, m), 7.15 (1H, t, $J = 7.2$ Hz), 4.79–4.77 (1H, m), 4.36–4.28 (2H, m), 2.45–2.42 (1H, m), 1.61–1.54 (3H, m), 1.51–1.46 (1H, m), 1.43–1.17 (15H, m), 0.92–0.82 (6H, m); ^{13}C NMR (CDCl_3) δ 196.7, 154.9, 140.5, 134.3, 127.3, 124.2, 123.8, 123.5, 62.4, 57.5, 52.2, 31.6, 31.6, 29.5, 29.2, 28.8, 26.1, 22.5, 14.5, 14.0, 13.9; IR (CHCl_3 , cm^{-1}) 3037, 3009, 1680, 1601, 1539, 1521, 1506, 1480, 1461, 1374, 1321, 1295. MS (EI): $m/z = 359$ (M^+). HRMS (EI): m/z calcd for $\text{C}_{22}\text{H}_{33}\text{NO}_3$: 359.2460; found: 359.2463.

Methyl 3-Butyl-4-oxo-2-phenyl-3,4-dihydroquinoline-1(2*H*)-carboxylate (4m). Pale yellow oil (49 mg, 72%): ^1H NMR (CDCl_3) δ 7.90 (2H, dd, $J = 7.9, 1.7$ Hz), 7.51–7.48 (1H, m), 7.22–7.14 (5H, m), 7.09 (1H, t, $J = 7.6$ Hz), 6.00 (1H, s), 3.93 (3H, s), 3.13 (1H, td, $J = 7.6, 2.1$ Hz), 1.80–1.74 (2H, m), 1.60–1.56 (1H, m), 1.49–1.45 (1H, m), 1.41–1.36 (2H, m), 0.92 (3H, t, $J = 7.6$ Hz); ^{13}C NMR (CDCl_3) δ 195.7, 155.6, 141.1, 138.3, 134.6, 128.6, 127.5, 126.6, 124.0, 123.6, 123.5, 60.2, 53.7, 51.2, 29.8, 29.2, 22.5, 13.9; IR (CHCl_3 , cm^{-1}) 3036, 3009, 1715, 1706, 1684, 1480, 1441. MS (EI): $m/z = 337$ (M^+). HRMS (EI): m/z calcd for $\text{C}_{21}\text{H}_{23}\text{NO}_3$: 337.1678; found: 337.1670.

Ethyl 3-Butyl-7-methoxy-4-oxo-2-phenyl-3,4-dihydroquinoline-1(2*H*)-carboxylate (4n). Pale yellow oil (40 mg, 52%): ^1H NMR (CDCl_3) δ 7.85 (1H, d, $J = 8.9$ Hz), 7.48 (1H, s), 7.25–7.15 (5H, m), 6.63 (1H, dd, $J = 8.9, 2.1$ Hz), 5.99 (1H, s), 4.47–4.42 (1H, m), 4.36–4.31 (1H, m), 3.85 (3H, s), 3.07–3.05 (1H, m), 1.77–1.72 (2H, m), 1.60–1.56 (1H, m), 1.49–1.43 (1H, m), 1.40–1.34 (5H, m), 0.92 (3H, t, $J = 7.6$ Hz); ^{13}C NMR (CDCl_3) δ 194.6, 164.6, 155.0, 143.0, 138.7, 129.5, 128.6, 127.4, 126.6, 117.4, 111.1, 107.7, 62.8, 60.1, 55.5, 50.9, 30.0, 29.3, 22.5, 14.5, 13.9; IR (CHCl_3 , cm^{-1}) 3036, 3009, 1706, 1700, 1675, 1603, 1498, 1448, 1311, 1271. MS (EI): $m/z = 381$ (M^+). HRMS (EI): m/z calcd for $\text{C}_{23}\text{H}_{27}\text{NO}_4$: 381.1940; found: 381.1940.

Methyl 4-Oxo-3-phenyl-2-*p*-tolyl-3,4-dihydroquinoline-1(2*H*)-carboxylate (4o). White solid (54 mg, 73%): mp 131–132 °C; ^1H NMR (CDCl_3) δ 8.00 (1H, dd, $J = 7.9, 1.7$ Hz), 7.82 (1H, d, $J = 7.6$ Hz), 7.53 (1H, t, $J = 7.9$ Hz), 7.31–7.13 (8H, m), 7.05 (2H, d, $J = 8.2$ Hz), 6.13 (1H, s), 4.42 (1H, d, $J = 1.4$ Hz), 3.62 (3H, s), 2.25 (3H, s); ^{13}C NMR (CDCl_3) δ 193.6, 155.3, 141.9, 137.4, 137.3, 135.2, 135.0, 129.4, 129.0, 127.7, 127.7, 127.4, 126.6, 125.0, 124.4, 124.2, 62.6, 56.1, 53.4, 20.9; IR (CHCl_3 , cm^{-1}) 3035, 1718, 1684, 1603, 1481, 1441, 1330, 1306. MS (EI): $m/z = 371$ (M^+). HRMS (EI): m/z calcd for $\text{C}_{24}\text{H}_{21}\text{NO}_3$: 371.1521; found: 371.1523.

Ethyl 4-Oxo-3-phenyl-2-*p*-tolyl-3,4-dihydroquinoline-1(2*H*)-carboxylate (4p). Pale yellow oil (51 mg, 66%): ^1H NMR (CDCl_3) δ 8.00 (1H, d, $J = 7.6$ Hz), 7.82 (1H, d, $J = 8.2$ Hz), 7.52 (1H, t, $J = 7.6$ Hz), 7.30–7.12 (8H, m), 7.05 (2H, d, $J = 7.6$ Hz), 6.14 (1H, s), 4.43 (1H, s), 4.12–4.05 (2H, m), 2.25 (3H, s), 1.04 (3H, t, $J = 6.9$ Hz); ^{13}C NMR (CDCl_3) δ 193.8, 154.8, 142.0, 137.4, 137.4, 135.3, 134.9, 129.4, 129.0, 127.8, 127.6, 127.3, 126.7, 125.1, 124.6, 124.1, 62.5, 56.0, 20.9, 14.2; IR

(CHCl₃, cm⁻¹) 3037, 3009, 1710, 1684, 1602, 1481, 1461, 1396, 1323, 1302. MS (EI): *m/z* = 385 (M⁺). HRMS (EI): *m/z* calcd for C₂₅H₂₃NO₃: 385.1678; found: 385.1683.

Ethyl 3-Butyl-2-(4-cyanophenyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (4q). White solid (62 mg, 82%): mp 137–138 °C; ¹H NMR (CDCl₃) δ 7.89 (1H, dd, *J* = 7.9, 1.7 Hz), 7.87 (1H, d, *J* = 8.9 Hz), 7.54–7.51 (3H, m), 7.31 (2H, d, *J* = 8.9 Hz), 7.12 (1H, t, *J* = 7.6 Hz), 6.04 (1H, s), 4.46–4.43 (1H, m), 4.38–4.36 (1H, m), 3.11 (1H, td, *J* = 7.6, 2.1 Hz), 1.80–1.75 (2H, m), 1.59–1.56 (1H, m), 1.49–1.45 (1H, m), 1.41–1.36 (5H, m), 0.92 (3H, t, *J* = 7.2 Hz); ¹³C NMR (CDCl₃) δ 194.9, 154.9, 144.1, 140.8, 134.9, 132.5, 127.6, 127.5, 124.3, 123.7, 123.2, 118.3, 111.6, 63.2, 59.8, 51.1, 29.7, 29.2, 22.5, 14.5, 13.9; IR (CHCl₃, cm⁻¹) 3037, 3009, 1715, 1685, 1602, 1480, 1462, 1378, 1322, 1296. MS (EI): *m/z* = 376 (M⁺). HRMS (EI): *m/z* calcd for C₂₃H₂₄N₂O₃: 376.1787; found: 376.1780.

Ethyl 4-Oxo-2-*p*-tolyl-3,4-dihydroquinoline-1(2H)-carboxylate (4s). White solid (53 mg, 85%): mp 114–115 °C; ¹H NMR (CDCl₃) δ 7.89 (1H, dd, *J* = 7.6, 1.4 Hz), 7.79 (1H, d, *J* = 8.2 Hz), 7.47–7.44 (1H, m), 7.09–7.05 (3H, m), 7.01 (2H, d, *J* = 8.2 Hz), 6.18 (1H, s), 4.42–4.34 (2H, m), 3.30–3.29 (2H, m), 2.22 (3H, s), 1.38 (3H, t, *J* = 7.2 Hz); ¹³C NMR (CDCl₃) δ 193.0, 154.5, 141.7, 137.2, 135.2, 134.5, 129.3, 126.8, 126.5, 125.0, 124.4, 124.0, 62.9, 55.8, 42.4, 20.9, 14.5; IR (CHCl₃, cm⁻¹) 3036, 3009, 1685, 1603, 1481, 1462, 1397, 1381, 1269. MS (EI): *m/z* = 309 (M⁺). HRMS (EI): *m/z* calcd for C₁₉H₁₉NO₃: 309.1365; found: 309.1364.

Ethyl 5-Fluoro-2-hexanoylphenylcarbamate (5d). Pale yellow oil (4 mg, 7%): ¹H NMR (CDCl₃) δ 11.45 (1H, br), 8.29 (1H, dd, *J* = 12.4, 2.7 Hz), 7.91 (1H, dd, *J* = 8.9, 6.2 Hz), 6.75–6.71 (1H, m), 4.23 (2H, q, *J* = 7.1 Hz), 2.96 (2H, t, *J* = 7.2 Hz), 1.73–1.71 (2H, m), 1.38–1.34 (4H, m), 1.32 (3H, t, *J* = 7.2 Hz), 0.92 (3H, t, *J* = 6.9 Hz); ¹³C NMR (CDCl₃) δ 203.4, 167.1, 153.8, 144.3, 144.2, 133.3, 133.3, 117.8, 108.6, 108.5, 106.3, 106.1, 61.4, 39.9, 31.4, 24.3, 22.5, 14.4, 13.9; IR (CHCl₃, cm⁻¹) 3036, 3009, 1730, 1653, 1591, 1529, 1458, 1251. MS (EI): *m/z* = 281 (M⁺). HRMS (EI): *m/z* calcd for C₁₅H₂₀NO₃F: 281.1427; found: 281.1428.

ASSOCIATED CONTENT

S Supporting Information. ¹H and ¹³C NMR spectra for all the new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*E-mail: ryanada@ps.hirokoku-u.ac.jp.

ACKNOWLEDGMENT

We are grateful to Dr. M. Nishi at Setsunan University for obtaining LRMS and HRMS data. This work was partially supported by a Grant-in-Aid for Scientific Research (C) from JSPS KAKENHI (23590032). N.O. is grateful for the Research Foundation by Hiroshima International University.

REFERENCES

- (a) Zhao, T.; Xu, B. *Org. Lett.* **2010**, *12*, 212–215. (b) Liu, Q.-L.; Li, Q.-L.; Fei, X.-D.; Zhu, Y.-M. *ACS Comb. Sci.* **2011**, *13*, 19–23.
- (a) Fokialakis, N.; Magiatis, P.; Terzis, A.; Tillequin, F.; Skaltsounis, A.-L. *Tetrahedron Lett.* **2001**, *42*, 5323–5325. (b) Gressler, V.; Stüker, C. Z.; Dias, G. O. C.; Dalcol, I. I.; Burrow, R. A.; Schmidt, J.; Wessjohann, L.; Morel, A. F. *Phytochemistry* **2008**, *69*, 994–999.
- Haddad, N.; Tan, J.; Farina, V. *J. Org. Chem.* **2006**, *71*, 5031–5034.

- (a) Hadjeri, M.; Peiller, E. L.; Beney, C.; Deka, N.; Lawson, M. A.; Dumontet, C.; Boumendjel, A. *J. Med. Chem.* **2004**, *47*, 4964–4970. (b) Lai, Y.-Y.; Huang, L.-J.; Lee, K.-H.; Xiao, Z.; Bastow, K. F.; Yamori, T.; Kuo, S.-C. *Bioorg. Med. Chem.* **2005**, *13*, 265–275.

- Lucero, B. d'A.; Gomes, C. R. B.; Frugulhetti, I. C. P. P.; Faro, L. V.; Alvarenga, L.; De Souza, M. C. B. V.; De Souza, T. M. L.; Ferreira, V. F. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 1010–1013.

- Huang, X.; Zhang, A.; Chen, D.; Jia, Z.; Li, X. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 2859–2863.

- Chou, L.-C.; Tsai, M.-T.; Hsu, M.-H.; Wang, S.-H.; Way, T.-D.; Huang, C.-H.; Lin, H.-Y.; Qian, K.; Dong, Y.; Lee, K.-H.; Huang, L.-J.; Kuo, S.-C. *J. Med. Chem.* **2010**, *53*, 8047–8058.

- Sato, M.; Kawakami, H.; Motomura, T.; Aramaki, H.; Matsuda, T.; Yamashita, M.; Ito, Y.; Matsuzaki, Y.; Yamataka, K.; Ikeda, S.; Shinkai, H. *J. Med. Chem.* **2009**, *52*, 4869–4882.

- (a) Xia, Y.; Yang, Z.-Y.; Xia, P.; Bastow, K. F.; Tachibana, Y.; Kuo, S.-C.; Hamel, E.; Hackl, T.; Lee, K.-H. *J. Med. Chem.* **1998**, *41*, 1155–1162. (b) Zhang, S.-X.; Kuo, S.-C.; Brossi, A.; Hamel, E.; Tropsha, A.; Lee, K.-H. *J. Med. Chem.* **2000**, *43*, 167–176.

- (a) Nieman, J. A.; Ennis, M. D. *Org. Lett.* **2000**, *2*, 1395–1397.

- (b) Nieman, J. A.; Ennis, M. D. *J. Org. Chem.* **2001**, *66*, 2175–2177. (c) Cheng, D.; Zhou, J.; Saiah, E.; Beaton, G. *Org. Lett.* **2002**, *4*, 4411–4414.

- (d) Hara, O.; Sugimoto, K.; Hamada, Y. *Tetrahedron* **2004**, *60*, 9381–9390. (e) Chandrasekhar, S.; Vijeender, K.; Sridhar, C. *Tetrahedron Lett.* **2007**, *48*, 4935–4937. (f) Yoshitomi, Y.; Arai, H.; Makino, K.; Hamada, Y. *Tetrahedron* **2008**, *64*, 11568–11579. (g) Lee, H.; Suzuki, M.; Cui, J.; Kozmin, S. A. *J. Org. Chem.* **2010**, *75*, 1756–1759.

- (11) Catalytic asymmetric syntheses of 2,3-dihydro-4-quinolones: (a) Shintani, R.; Yamagami, T.; Kimura, T.; Hayashi, T. *Org. Lett.* **2005**, *7*, 5317–5319. (b) Lei, B.-L.; Ding, C.-H.; Yang, X.-F.; Wan, X.-L.; Hou, X.-L. *J. Am. Chem. Soc.* **2009**, *131*, 18250–18251. (c) Liu, X.; Lu, Y. *Org. Lett.* **2010**, *12*, 5592–5595.

- (12) (a) Okamoto, N.; Miwa, Y.; Minami, H.; Takeda, K.; Yanada, R. *Angew. Chem., Int. Ed.* **2009**, *48*, 9693–9696. (b) Okamoto, N.; Takeda, K.; Yanada, R. *J. Org. Chem.* **2010**, *75*, 7615–7625.

- (13) Intermolecular alkyne-carbonyl metathesis: (a) Hsung, R. P.; Zificsak, C. A.; Wei, L.-L.; Douglas, C. J.; Xiong, H.; Mulder, J. A. *Org. Lett.* **1999**, *1*, 1237–1240. (b) Viswanathan, G. S.; Li, C.-J. *Tetrahedron Lett.* **2002**, *43*, 1613–1615. (c) Rhee, J. U.; Michael, J.; Krische, M. J. *Org. Lett.* **2005**, *7*, 2493–2495. (d) Saito, A.; Kasai, J.; Odaira, Y.; Fukaya, H.; Hanzawa, Y. *J. Org. Chem.* **2009**, *74*, 5644–5647.

- (14) Intramolecular alkyne-carbonyl metathesis: (a) Kurtz, K. C. M.; Hsung, R. P.; Zhang, Y. *Org. Lett.* **2006**, *8*, 231–234. (b) Jin, T.; Yamamoto, Y. *Org. Lett.* **2007**, *9*, 5259–5262. (c) Jin, T.; Yamamoto, Y. *Org. Lett.* **2008**, *10*, 3137–3139. (d) González-Rodríguez, C.; Escalante, L.; Varela, L. A.; Castedo, L.; Saá, C. *Org. Lett.* **2009**, *11*, 1531–1533. (e) Bera, K.; Sarkar, S.; Biswas, S.; Maiti, S.; Jana, U. *J. Org. Chem.* **2011**, *76*, 3539–3544.

- (15) Jacubert, M.; Provot, O.; Peyrat, J.-F.; Hamze, A.; Brion, J.-D.; Alami, M. *Tetrahedron* **2010**, *66*, 3775–3787.

- (16) The stereochemistry of the product **4** was determined by the values of the vicinal coupling constants between protons at the 2- and 3-positions.

- (17) Wu, M.-J.; Chang, L.-J.; Wei, L.-M.; Lin, C.-F. *Tetrahedron* **1999**, *55*, 13193–13200.